Healthcare and Technology companies are always looking to utilize M&A as a means to drive shareholder value despite market cycles and uncertainties.
As our track record demonstrates, we partner with our clients to deliver deep sector insights and broad connectivity to provide trusted advice.
Recent Transactions
See all transactions
UNDISCLOSED
Up to $291 Million
UNDISCLOSED
$84 Million
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
UNDISCLOSED
Up to CHF 200 MILLION
UNDISCLOSED
Team
SVB Securities’s M&A Advisory team is led by senior, experienced professionals with over 20 years’ experience and long-term relationships with healthcare consolidators. Our team is uniquely focused on our clients’ success and value creating transactions.
Healthcare M&A Team
Jed Brody
Senior Managing Director, Healthcare Mergers & Acquisitions
Jed Brody is a Senior Managing Director of Healthcare Investment Banking at SVB Securities. With over 20 years of experience, he will lead the firm’s M&A advisory business across major sectors of healthcare, including healthcare-focused private equity.
Jed joined the firm in 2021 from Barclays where he most recently was Co-Head of Healthcare Americas and Global Head of Healthcare M&A. While at Barclays, he worked on many transactions including, but not limited to, CVS Health’s $69 billion acquisition of Aetna, ICU Medical’s $2.35 billion acquisition of Smiths Medical, the sale of Equian to UnitedHealth Group for $2.35 billion, the sale of Kindred Healthcare to Lifepoint, Sun Life’s $2.5 billion acquisition of DentaQuest, Centene’s $17.3 billion acquisition of WellCare. Prior to this, he was at Lehman Brothers.
He earned his BS in Finance from Lehigh University.
Dan Lepanto
Senior Managing Director, Healthcare Mergers & Acquisitions
Dan Lepanto is a Senior Managing Director at SVB Securities and leads the Biopharma Mergers & Acquisitions team.
Prior to joining the firm in 2008, Dan spent 10 years at Cowen and Company where he executed a range of biopharma M&A transactions. Dan began his career in the Mergers & Acquisitions group at Wasserstein Perella. He has advised on a number of biopharma and health care transactions over the span of his career including the sale of Dicerna to Novo Nordisk, the sale of Dermira to Eli Lilly, the sale of NPS to Shire, the sale of Cynosure to Hologic, the sale of TKT to Shire, the sale of GelTex to Genzyme, the merger of Total Renal Care with Renal Treatment Centers and the acquisition of Vivra by Gambro.
He earned his B.S. in Finance with High Honors from Pennsylvania State University.